Patient imaging and treatment data hub for targeted radiotherapies
Core 3: Patient Data
This effort collects scans, dose measurements, and outcome data from people getting targeted radiopharmaceutical therapy so researchers can link images to treatment response and side effects.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11180199 on NIH RePORTER |
What this research studies
If you take part, Johns Hopkins will enroll patients receiving radiopharmaceutical therapies and perform a master imaging protocol called SeeToTreat to capture scans, dosimetry, and clinical outcomes. The Core will combine data from patients getting standard-of-care or research RPT and from industry partners working with agents such as HER2-, PSMA-, and DOTATATE-targeted therapies. Collected images and de-identified clinical data will be pooled into a shared database of absorbed dose, tumor response, and toxicity to support the P01 projects. This effort aims to let researchers compare imaging and dose across different agents and centers to improve treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates are people receiving or about to receive radiopharmaceutical therapy (including HER2-, PSMA-, or DOTATATE-targeted RPT) at Johns Hopkins or a participating collaborator, whether on standard-care or research protocols.
Not a fit: Patients who are not receiving radiopharmaceutical therapies or who cannot come to participating sites for imaging are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this could help personalize radiopharmaceutical dosing and improve prediction of who will respond or experience side effects.
How similar studies have performed: Previous dosimetry and imaging registries have provided useful insights for individual agents, but pooling multi-agent, multi-center imaging and dose data as planned here is relatively novel.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Kiess, Ana Ponce — Johns Hopkins University
- Study coordinator: Kiess, Ana Ponce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.